GSK and Spero win Utebzi approval after an earlier FDA rejection and new Phase 3 trial
The first United States-approved oral carbapenem could replace intravenous therapy for selected complicated urinary tract infections, but stewardship, four-times-daily dosing and resistance risks will constrain its use.
